Spectrum Therapeutics provides update on its global clinical research program and unveils pharmacovigilance program

Spectrum Therapeutics provides update

on its global clinical research program and unveils pharmacovigilance program

SMITHS FALLS, ON, June 5, 2019 /CNW/ - Spectrum

Therapeutics ("Spectrum"), the medical division of Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) (the "Company"

or "Canopy Growth") is pleased to share an update on its efforts to develop and commercialize validated cannabis medicines

through clinical trials. Demand for cannabinoid-based medicines is emerging around the world. With a highly experienced scientific

team and the resources needed to conduct robust clinical trials, Spectrum Therapeutics is pursuing research to introduce products

for the therapeutic areas of pain, mood and sleep and to gain access to new markets independent of medical cannabis laws.

Spectrum Therapeutics is focused over the next

24 months to further the science of cannabinoids and provide evidence by way of clinical trials on what conditions medical cannabis

can treat. (CNW Group/Spectrum Therapeutics)

Spectrum Therapeutics is focused over the next 24 months to further the science of cannabinoids and provide evidence by way of

clinical trials on what conditions medical cannabis can treat. This research includes product design and ingredient selection,

formulation, and safety and efficacy testing towards the development of standardized cannabis drug formulations and dose delivery

systems. Research activity is occurring in two main areas: registration trials and exploratory studies.

Registration trials begin with phase I studies

of cannabinoid products covering a spectrum of proprietary THC and CBD ratios. These initial trials provide critical dosing and

safety data to inform subsequent phase II trials. Spectrum Therapeutics is pleased to announce that two phase I trials have already

been completed, one each in Canada and Chile.

Exploratory "proof of concept" studies

use a range of Spectrum products and design methodologies to explore different dose responses, and safety and efficacy signals

for target conditions. Those that show promising results will be added to the registration trial pipeline and their initial findings

will allow for optimal phase II trial design. The first proof of concept phase IIb "in human" clinical trial previously

announced by the Company, to evaluate the use of medical cannabis for treating insomnia, is in progress in partnership with Drs.

Julie Carrier and Alex Desautels at the Universit de Montr al. It is expected to be completed by calendar Q2 2020

with results announced by calendar Q3 2020.

Other proof of concept studies are currently

underway in partnership with researchers including Dr. Bernard Le Foll at the Centre for Addiction and Mental Health, Dr. Mary-Ann

Fitzcharles at McGill University, and Dr. Angela Genge at the Montreal Neurological Institute. Over twenty conditions are being

examined across these studies, including pain, sleep, and mood/anxiety disorders. Spectrum Therapeutics is also exploring areas

such as neurodegenerative disorders in addition to the previously announced research partnership with NEEKA Health Canada and the

NHL Alumni Association which is examining the efficacy of CBD-based therapies as part of a treatment for concussion symptoms. This

clinical trial is expected to register its first patients by October 2019 with preliminary results by July 2020.

Recently acquired C3 Cannabinoid

Compound Company ("C3") is currently progressing a clinical trial for the use of dronabinol to treat spasticity

due to multiple sclerosis. Additionally, research on the potential of medical cannabis to treat cancer-related pain is also in

the works with Beckley Canopy Therapeutics, a partnership established between U.K. drug research institute, The Beckley Foundation

and Canopy Growth. Patient registrations for this trial are expected in September 2019.

To support its research program, Spectrum Therapeutics

is pleased to announce the appointment of Dr. Marcel Bonn-Miller as Global Clinical Scientific Director. He brings to the team

18 years of experience researching cannabinoids and their various effects, has received funding for 27 research grants, and has

led or contributed to 19 clinical trials. His work has been featured in 139 academic publications and 161 conference presentations,

and he also serves on the editorial boards of five academic journals. Dr. Bonn-Miller previously worked as Director of Cannabinoid

Research for Zynerba Pharmaceuticals, a leading transdermal cannabinoid pharmaceutical company. He is also an adjunct Assistant

Professor at the University of Pennsylvania Perelman School of Medicine, known for his work examining the potential of cannabis

in treating post-traumatic stress disorder.

Dr. Bonn-Miller will be supported by Hunter

Land and Drs. Ryan Lanier and Erica Peters as Associate Directors. Land was instrumental in bringing the first cannabis-derived

CBD medicine developed for patients with treatment-resistant forms of epilepsy, including Dravet and Lennox-Gastaut syndromes,

to FDA approval. Dr. Peters was the lead clinical cannabis scientist for four years at Battelle, the world's largest non-profit

research and development organization, and Dr. Lanier worked for Analgesic Solutions where he consulted on the development of pain

medications for FDA approval.

In the interest of patient safety and good

clinical practice, Spectrum Therapeutics is pleased to announce the implementation of a unique global pharmacovigilance program

to capture and document adverse events reported from the worldwide use of its medical cannabis products in addition to the Company's

Canadian recreational cannabis brands including Tweed and DNA Genetics, and its CBD product offerings.

Pharmacovigilance, also known as drug safety,

is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects

from the use of pharmaceutical products. While Spectrum Therapeutics and Canopy Growth were already reporting any adverse reactions

to its cannabis products as per Health Canada regulations, the launch of this global pharmacovigilance program ensures that all

employees are trained on how to identify and report adverse events. The Company's internal Pharmacovigilance team is responsible

for analyzing and entering events into a global safety database compliant with regional regulatory requirements.

A global independent safety monitoring board

chaired by Professor Yola Moride at the Universit de Montr al will periodically review adverse event summaries and

advise the Spectrum Therapeutics scientific team regarding product safety and clinical trial design.

"We believe that this strategic approach

to global clinical research, in collaboration with outstanding investigators and institutions, and supported by our first-rate

team of scientists, will generate innovative products for a number of indications with significant unmet needs," commented

Dr. Mark Ware, Chief Medical Officer, Canopy Growth. "We are also pleased to announce the launch of our global pharmacovigilance

program whereby every one of our 3000+ staff worldwide are trained in reporting adverse events. It's an important step towards

establishing drug safety and will advance our efforts to provide patients with accepted, clinically validated cannabis medicines

while transparently demonstrating the relative risks of cannabis."

Here's to (Clinically Validated) Future Growth.

About Canopy Growth Corporation

Canopy Growth (TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, hemp and cannabis device company, offering distinct

brands and curated cannabis varieties in dried, oil and Softgel capsule forms, as well as medical devices through the Company's

subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven

by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.

The Company has operations in over a dozen countries across five continents.

The Company's medical division, Spectrum Therapeutics

is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding

of cannabis, and has devoted millions of dollars toward cutting edge, commercializable research and IP development. Spectrum Therapeutics

sells a range of full-spectrum products using its colour-coded classification Spectrum system as well as single cannabinoid Dronabinol

under the brand Bionorica Ethics.

The Company operates retail stores across Canada

under its award-winning Tweed and Tokyo Smoke banners. Tweed is a globally recognized cannabis brand which has built a large and

loyal following by focusing on quality products and meaningful customer relationships.

From our historic public listing on the Toronto

Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through

leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including

cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and Green House Seeds, and Fortune 500 alcohol leader Constellation

Brands, to name but a few. Canopy Growth operates ten licensed cannabis production sites with over 4.4 million square feet of production

capacity, including over one million square feet of GMP certified production space. For more information visit www.canopygrowth.com

Notice Regarding Forward Looking Statements

This news release contains "forward-looking statements" within the meaning of the United States Private Securities Litigation

Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation.

Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans",

"expects" or "does not expect", "is expected", "estimates", "intends", "anticipates"

or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions,

events or results "may", "could", "would", "might" or "will" be taken, occur